/ /

Cheryl Guttman Krader
End-stage glaucoma requires outside-of-the-box management
Although the aim of glaucoma management is to maintain visual function, the role of the ophthalmologist does not end once a patient has lost useful vision. Robert L. Stamper, MD, discussed care for patients with end-stage glaucoma.
Evolution in glaucoma surgery mounting with MIGS procedures
An expanding armamentarium of minimally invasive and micro-invasive glaucoma surgery procedures is transforming glaucoma management.
Novel drug delivery platforms: Filling a ‘GAP’ in glaucoma
Medical therapy for glaucoma is not becoming obsolete, but it is evolving away from conventional topical administration.
Home-monitoring devices offer better insight to figure out IOP
L. Jay Katz, MD. outlined the benefits of home IOP monitoring. These devices will offer a wealth of information that should lead to increased understanding of glaucoma and better patient care.
Micropulse probe transforms transscleral cyclophotocoagulation
Micropulse transscleral cyclophotocoagulation with a diode laser is demonstrating promising efficacy with better safety and tolerability than traditional TSCPC.
Anti-PDGF inhibitor development continues despite negative results
Despite the failure of 2 clinical trials involving a combination therapy of platelet-derived growth factor (PDGF) inhibitor and anti-vascular endothelial growth factor (anti-VEGF) therapy, a third phase III study continues.
5-year CATT analysis finds anti-VEGF drugs a long-term AMD therapy
After 5 years of follow-up in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), the visual acuity gains achieved during the first 2 years of anti-VEGF treatment were not maintained, the choroidal neovascular lesions continued to evolve with evidence of persistent activity in some eyes, and there was increased retinal thinning and geographic atrophy (GA).
Selective techniques revolutionize treatment for retinoblastoma
Advancements in retinoblastoma have occurred in the areas of treatment, genetic testing, and diagnostic imaging.
Endoillumination growth amplifies tissue visualization
Endoillumination for vitreoretinal surgery continues to improve with the introduction of brighter, safer light sources with color filters that may allow opportunities for better tissue visualization.
Access, costs of bevacizumab key factors for DME therapy
The efficacy of intravitreal bevacizumab (Avastin, Genentech) for improving vision in patients with center-involving diabetic macular edema (DME) has been demonstrated in several clinical trials.

Poll